Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, double-masked, randomized, placebo-controlled, parallel-group,
efficacy, safety, and tolerability study evaluating the efficacy of Dupilumab in the
treatment of signs and symptoms of atopic keratoconjunctivitis (AKC).
Phase:
Phase 2
Details
Lead Sponsor:
Andover Eye Associates
Collaborators:
Regeneron Pharmaceuticals Statistics & Data Corporation